Arrowstreet Capital
OMED

Arrowstreet Capital’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Arrowstreet Capital’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-16,629
Closed -$190K – 2977
2016
Q3 		$190K Buy
+16,629
New +$194K ﹤0.01% 1429

Other funds holding OMED

ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowstreet Capital's OMED Position: Q4 2016 in Review

Arrowstreet Capital sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2016, closing a stake of 16,629 shares — an estimated $190K sold.

Arrowstreet Capital first reported a position in OMED in Q3 2016 and held it in 1 quarter. The position peaked at $190K in Q3 2016. 86 funds tracked by Wall St. Rank hold OMED as of Q4 2016.

  • Arrowstreet Capital reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Arrowstreet Capital sold 16,629 OncoMed Pharmaceuticals, Inc. shares in Q4 2016, an estimated $190K.
  • Arrowstreet Capital first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2016 and held it in 1 quarter.
  • Arrowstreet Capital's OncoMed Pharmaceuticals, Inc. position peaked at $190K in Q3 2016.
  • 86 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2016.

Based on Arrowstreet Capital's 13F filing for Q4 2016, filed 15 Feb 2017.